Traditionally, isotope dilution kinetic studies of glucose, FFA, and amino acid metabolism in humans have primarily used intravenous infusion (and oral administration when tracing enteral absorption) ...

Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Paolo Ferrigno Product Manager prefilled syringes and cartridges Datwyler Healthcare ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Merck has talked up the value of its subcutaneous version of Keytruda, arguing that the investigational therapy will increase access to treatment by untethering patients from infusion centers. Roche ...

BD (Becton, Dickinson and Company), a leading global medical technology company, announces the approval of the BD Saf-T-Intima™ Safety Integrated IV Catheter System for use in subcutaneous infusion ...

Allen CH, Etzwiler LS, Miller MK, et al for the Increased Flow Utilizing Subcutaneously-Enabled-(INFUSE) Pediatric Rehydration Study Collaborative Research Group Oral rehydration is the preferred ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...